7 completed, 2 withdrawn. 5 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 4, Withdrawn 1 |
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow bavisant: new trials by email Literature Review of bavisant trials Research Report on bavisant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness BEN-2001, Placebo - Excessive Daytime Sleepiness, Parkinson Disease | Phase 2 | Completed | BenevolentAI Bio | 244 | 2017-11-10 | 2025-03-10 |
| Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults JNJ-31001074, Placebo - Alcoholism | Phase 2 | Withdrawn | Janssen Research & Development, LLC | 2011-08-01 | 2012-04-30 | |
| A Drug Interaction Study of JNJ-31001074 and Ketoconazole in Healthy Volunteers JNJ-31001074; ketoconazole - Healthy, Pharmacokinetics | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 14 | 2009-11-01 | 2010-04-30 |
| A Study to Characterize the Pharmacokinetics and Effect of Food on JNJ-31001074 in Healthy Volunteers JNJ-31001074 - Healthy, Pharmacokinetics | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 20 | 2009-06-01 | 2010-04-26 |
| A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of JNJ-31001074 in Pediatric Patients (12-17 Years) With Attention Deficit Hyperactivity Disorder (ADHD) JNJ-31001074 - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 18 | 2009-05-01 | 2010-04-16 |
| A Study to Evaluate Pharmacokinetics, Safety and Tolerability After a Single Dose Administration of of JNJ-31001074 in Children (6-11 Years) With Attention Deficit Hyperactivity Disorder (ADHD) JNJ-31001074 - Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity | Phase 1 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 18 | 2009-05-01 | 2010-04-16 |
| A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 430 | 2009-05-01 | 2013-03-04 |
| A Safety and Effectiveness Study of JNJ-31001074 in Adults With Attention-Deficit/Hyperactivity Disorder. Placebo, JNJ-31001074 - Attention Deficit Hyperactivity Disorder | Phase 2 | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 32 | 2007-12-01 | 2014-05-13 |
| A Study to Evaluate the Pharmacokinetic Drug Interaction Between Multiple Doses of JNJ-31001074 and a Single Dose of an Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel in Women JNJ-31001074 - Pharmacokinetics, Drug Interactions | Phase 1 | Withdrawn | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2016-09-20 |
Attention Deficit Disorder with Hyperactivity (4) · Alcohol-Related Disorders (1) · Alcoholism (1) · Disorders of Excessive Somnolence (1) · Mental Disorders (1) · Parkinson Disease (1) · Substance-Related Disorders (1)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (7) · BenevolentAI Bio (1) · Janssen Research & Development, LLC (1)
United States (4)